Skip to content

Study · Randomized controlled trial · n = 300 · 2022

12 results

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S

The lancet. Diabetes & endocrinology4 Feb 2022Cited by 249 (Europe PMC)

PMID35131037 (opens in a new tab)DOI10.1016/s2213-8587(22)00008-0 (opens in a new tab)PepBankPUB-35131037
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In east Asian adults with obesity, semaglutide 2.4 mg lowered bodyweight by 11.1 percentage points more than placebo at week 68.

    In plain wordsIn east Asian adults with obesity, semaglutide 2.4 mg led to more weight loss than placebo over 68 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in bodyweight at week 68
    Study

    n = 300

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Mean bodyweight change
    −13.2%
    semaglutide 2.4 mg
    ETD vs placebo
    −11.1 percentage points
    2.4 mg

    Source sentences

    Summary
    Estimated mean change in bodyweight from baseline to week 68 was -13·2% (SEM 0·5) in the semaglutide 2·4 mg group and -9·6% (0·8) in the semaglutide 1·7 mg group versus -2·1% (0·8) in the placebo group
    3 context sentences
    Summary · context
    estimated treatment difference [ETD] -11·1 percentage points [95% CI -12·9 to -9·2] for semaglutide 2·4 mg vs placebo
    Summary · context
    In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes.
    Summary · context
    Participants were randomly assigned (4:1:2:1) to once-weekly subcutaneous semaglutide 2·4 mg or matching placebo, or semaglutide 1·7 mg or matching placebo, plus lifestyle recommendations for 68 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In east Asian adults with obesity, more participants on semaglutide 2.4 mg than on placebo achieved a weight reduction of 5% or more (83% versus 21%).

    In plain wordsIn east Asian adults with obesity, more people on semaglutide 2.4 mg than on placebo lost at least 5% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchieved at least 5% bodyweight reduction at week 68
    Study

    n = 293

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Proportion with >=5% weight reduction
    83%
    semaglutide 2.4 mg
    Odds ratio vs placebo
    21.7 OR
    2.4 mg

    Source sentences

    Summary
    160 [83%] of 193 participants) and semaglutide 1·7 mg group (71 [72%] of 98 participants) than in the placebo group (21 [21%] of 100 participants)
    3 context sentences
    Summary · context
    odds ratio [OR] 21·7 [95% CI 11·3 to 41·9] for semaglutide 2·4 mg vs placebo
    Summary · context
    In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes.
    Summary · context
    Participants were randomly assigned (4:1:2:1) to once-weekly subcutaneous semaglutide 2·4 mg or matching placebo, or semaglutide 1·7 mg or matching placebo, plus lifestyle recommendations for 68 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In east Asian adults with obesity, semaglutide 1.7 mg lowered bodyweight by 7.5 percentage points more than placebo at week 68.

    In plain wordsIn east Asian adults with obesity, semaglutide 1.7 mg led to more weight loss than placebo over 68 weeks.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage change in bodyweight at week 68
    Study

    n = 202

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Mean bodyweight change
    −9.6%
    semaglutide 1.7 mg
    ETD vs placebo
    −7.5 percentage points
    1.7 mg

    Source sentences

    Summary
    Estimated mean change in bodyweight from baseline to week 68 was -13·2% (SEM 0·5) in the semaglutide 2·4 mg group and -9·6% (0·8) in the semaglutide 1·7 mg group versus -2·1% (0·8) in the placebo group
    3 context sentences
    Summary · context
    -7·5 percentage points [95% CI -9·6 to -5·4] for semaglutide 1·7 mg vs placebo
    Summary · context
    In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes.
    Summary · context
    Participants were randomly assigned (4:1:2:1) to once-weekly subcutaneous semaglutide 2·4 mg or matching placebo, or semaglutide 1·7 mg or matching placebo, plus lifestyle recommendations for 68 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In east Asian adults with obesity, more participants on semaglutide 1.7 mg than on placebo achieved a weight reduction of 5% or more (72% versus 21%).

    In plain wordsIn east Asian adults with obesity, more people on semaglutide 1.7 mg than on placebo lost at least 5% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseAchieved at least 5% bodyweight reduction at week 68
    Study

    n = 198

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Proportion with >=5% weight reduction
    72%
    semaglutide 1.7 mg
    Odds ratio vs placebo
    11.1 OR
    1.7 mg

    Source sentences

    Summary
    71 [72%] of 98 participants) than in the placebo group (21 [21%] of 100 participants)
    3 context sentences
    Summary · context
    OR 11·1 [95% CI 5·5 to 22·2] for semaglutide 1·7 mg vs placebo
    Summary · context
    In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes.
    Summary · context
    Participants were randomly assigned (4:1:2:1) to once-weekly subcutaneous semaglutide 2·4 mg or matching placebo, or semaglutide 1·7 mg or matching placebo, plus lifestyle recommendations for 68 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In east Asian adults with obesity, semaglutide 2.4 mg reduced abdominal visceral fat area by 40.0% versus 6.9% with placebo.

    In plain wordsIn east Asian adults with obesity, semaglutide 2.4 mg cut belly visceral fat area more than placebo did.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in abdominal visceral fat area
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Visceral fat area change
    −40%
    semaglutide 2.4 mg
    ETD vs placebo
    −33.2%
    2.4 mg

    Source sentences

    Summary
    Abdominal visceral fat area was reduced by 40·0% (SEM 2·6) among participants in the semaglutide 2·4 mg group and 22·2% (3·7) among participants in the semaglutide 1·7 mg group versus 6·9% (3·8) in the placebo group
    4 context sentences
    Summary · context
    ETD -33·2% [95% CI -42·1 to -24·2] for semaglutide 2·4 mg vs placebo
    Summary · context
    Change in abdominal visceral fat area was assessed as a supportive secondary endpoint using computed tomography scanning in a subset of participants.
    Summary · context
    In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes.
    Summary · context
    Participants were randomly assigned (4:1:2:1) to once-weekly subcutaneous semaglutide 2·4 mg or matching placebo, or semaglutide 1·7 mg or matching placebo, plus lifestyle recommendations for 68 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In east Asian adults with obesity, semaglutide 1.7 mg reduced abdominal visceral fat area by 22.2% versus 6.9% with placebo.

    In plain wordsIn east Asian adults with obesity, semaglutide 1.7 mg cut belly visceral fat area more than placebo did.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in abdominal visceral fat area
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Visceral fat area change
    −22.2%
    semaglutide 1.7 mg
    ETD vs placebo
    −15.3%
    1.7 mg

    Source sentences

    Summary
    Abdominal visceral fat area was reduced by 40·0% (SEM 2·6) among participants in the semaglutide 2·4 mg group and 22·2% (3·7) among participants in the semaglutide 1·7 mg group versus 6·9% (3·8) in the placebo group
    4 context sentences
    Summary · context
    -15·3% [95% CI -25·6 to -4·9] for semaglutide 1·7 mg vs placebo
    Summary · context
    Change in abdominal visceral fat area was assessed as a supportive secondary endpoint using computed tomography scanning in a subset of participants.
    Summary · context
    In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, we assessed the effect of semaglutide versus placebo for weight management in adults from east Asia with obesity, with or without type 2 diabetes.
    Summary · context
    Participants were randomly assigned (4:1:2:1) to once-weekly subcutaneous semaglutide 2·4 mg or matching placebo, or semaglutide 1·7 mg or matching placebo, plus lifestyle recommendations for 68 weeks.
  7. 07HumanRandomized controlled trialSafety outcome

    In east Asian adults with obesity, adverse events were reported by 86% on semaglutide 2.4 mg versus 79% on placebo.

    In plain wordsIn east Asian adults with obesity, most people on semaglutide 2.4 mg or placebo reported some adverse event.

    Peptide
    Semaglutide
    Outcome
    Not applicableAny adverse event
    Study

    n = 300

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Adverse events
    86%
    semaglutide 2.4 mg

    Source sentences

    Summary
    171 (86%) of 199 participants in the semaglutide 2·4 mg group, 82 (82%) of 100 participants in the semaglutide 1·7 mg group, and 80 (79%) of 101 participants in the placebo group reported adverse events.
  8. 08HumanRandomized controlled trialSafety outcome

    In east Asian adults with obesity, gastrointestinal disorders occurred in 59% on semaglutide 2.4 mg versus 30% on placebo, mostly mild to moderate.

    In plain wordsIn east Asian adults with obesity, gut problems were more common with semaglutide 2.4 mg than with placebo, mostly mild to moderate.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal disorders
    Study

    n = 300

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Gastrointestinal disorders
    59%
    semaglutide 2.4 mg

    Source sentences

    Summary
    Gastrointestinal disorders, which were mostly mild to moderate, were reported in 118 (59%) of 199 participants in the semaglutide 2·4 mg group, 64 (64%) of 100 participants in the semaglutide 1·7 mg group, and 30 (30%) of 101 participants in the placebo group.
  9. 09HumanRandomized controlled trialSafety outcome

    In east Asian adults with obesity, adverse events led to discontinuation in 3% on semaglutide 2.4 mg versus 1% on placebo.

    In plain wordsIn east Asian adults with obesity, few people stopped semaglutide 2.4 mg because of side effects.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events leading to discontinuation
    Study

    n = 300

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Discontinuation for AEs
    3%
    semaglutide 2.4 mg

    Source sentences

    Summary
    Adverse events leading to trial product discontinuation occurred in five (3%) of 199 participants in the semaglutide 2·4 mg group, three (3%) of 100 participants in the semaglutide 1·7 mg group, and one (1%) of 101 participants in the placebo group.
  10. 10HumanRandomized controlled trialSafety outcome

    In east Asian adults with obesity, adverse events were reported by 82% on semaglutide 1.7 mg versus 79% on placebo.

    In plain wordsIn east Asian adults with obesity, most people on semaglutide 1.7 mg or placebo reported some adverse event.

    Peptide
    Semaglutide
    Outcome
    Not applicableAny adverse event
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Adverse events
    82%
    semaglutide 1.7 mg

    Source sentences

    Summary
    171 (86%) of 199 participants in the semaglutide 2·4 mg group, 82 (82%) of 100 participants in the semaglutide 1·7 mg group, and 80 (79%) of 101 participants in the placebo group reported adverse events.
  11. 11HumanRandomized controlled trialSafety outcome

    In east Asian adults with obesity, gastrointestinal disorders occurred in 64% on semaglutide 1.7 mg versus 30% on placebo, mostly mild to moderate.

    In plain wordsIn east Asian adults with obesity, gut problems were more common with semaglutide 1.7 mg than with placebo, mostly mild to moderate.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal disorders
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Gastrointestinal disorders
    64%
    semaglutide 1.7 mg

    Source sentences

    Summary
    Gastrointestinal disorders, which were mostly mild to moderate, were reported in 118 (59%) of 199 participants in the semaglutide 2·4 mg group, 64 (64%) of 100 participants in the semaglutide 1·7 mg group, and 30 (30%) of 101 participants in the placebo group.
  12. 12HumanRandomized controlled trialSafety outcome

    In east Asian adults with obesity, adverse events led to discontinuation in 3% on semaglutide 1.7 mg versus 1% on placebo.

    In plain wordsIn east Asian adults with obesity, few people stopped semaglutide 1.7 mg because of side effects.

    Peptide
    Semaglutide
    Outcome
    Not applicableAdverse events leading to discontinuation
    Study

    n = 201

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Discontinuation for AEs
    3%
    semaglutide 1.7 mg

    Source sentences

    Summary
    Adverse events leading to trial product discontinuation occurred in five (3%) of 199 participants in the semaglutide 2·4 mg group, three (3%) of 100 participants in the semaglutide 1·7 mg group, and one (1%) of 101 participants in the placebo group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03811574

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

Novo Nordisk A/Sn = 40121 Jan 2019 to 20 Nov 2020

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 22 Mar 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.